Verzenio/Verzenios (abemaciclib) vs Piqray (alpelisib)
Verzenio/Verzenios (abemaciclib) vs Piqray (alpelisib)
Verzenio (abemaciclib) and Piqray (alpelisib) are both targeted therapies used in the treatment of certain types of breast cancer, but they work in different ways and are used for different subtypes of the disease. Verzenio is a CDK4/6 inhibitor that is typically prescribed for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer, often in combination with an aromatase inhibitor or fulvestrant. Piqray, on the other hand, is a PI3K inhibitor indicated for postmenopausal women, and men, with HR+, HER2- advanced or metastatic breast cancer with a PIK3CA mutation, after progression on or after an endocrine-based regimen. The choice between Verzenio and Piqray would depend on the specific characteristics of the cancer, such as hormone receptor status and the presence of a PIK3CA mutation, as well as the patient's prior treatments and overall health profile. It is important for patients to discuss with their healthcare provider to determine the most appropriate treatment option based on their individual condition.
Difference between Verzenio/Verzenios and Piqray
Metric | Verzenio/Verzenios (abemaciclib) | Piqray (alpelisib) |
---|---|---|
Generic name | Abemaciclib | Alpelisib |
Indications | Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer | HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer |
Mechanism of action | CDK4 & CDK6 inhibitor | PI3K inhibitor, specifically the alpha isoform |
Brand names | Verzenio, Verzenios | Piqray |
Administrative route | Oral | Oral |
Side effects | Diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, decreased appetite, vomiting, headache | Hyperglycemia, rash, diarrhea, decreased lymphocyte count, increased GGT, nausea, fatigue, decreased appetite, stomatitis, vomiting, weight loss, hair loss |
Contraindications | Patients with a history of severe hypersensitivity to abemaciclib or any of its excipients | Patients with severe hypersensitivity to alpelisib or any of its excipients |
Drug class | Antineoplastic agent, kinase inhibitor | Antineoplastic agent, kinase inhibitor |
Manufacturer | Eli Lilly and Company | Novartis Pharmaceuticals Corporation |
Efficacy
Verzenio (Abemaciclib) in Breast Cancer Treatment
Verzenio, also known as abemaciclib, is a targeted therapy drug used in the treatment of certain types of breast cancer. Specifically, it is indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Verzenio works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are enzymes that promote the growth of cancer cells. Clinical trials have demonstrated that when used in combination with an aromatase inhibitor or fulvestrant, Verzenio can significantly improve progression-free survival in patients with this subtype of breast cancer. Additionally, it has been shown to be beneficial as a monotherapy in patients who have previously undergone endocrine therapy.
Piqray (Alpelisib) in Breast Cancer Management
Piqray, or alpelisib, is another medication used in the management of breast cancer, specifically for postmenopausal women, and men, with HR+, HER2- advanced or metastatic breast cancer with a PIK3CA mutation, after disease progression following an endocrine-based regimen. Piqray is a PI3K inhibitor that targets a specific genetic mutation and works by blocking the PI3K pathway, thereby inhibiting tumor growth. In clinical studies, Piqray, in combination with fulvestrant, has shown to significantly extend progression-free survival compared to fulvestrant alone in patients with a PIK3CA mutation. The presence of this mutation can be identified through an FDA-approved test, which is essential to determine the suitability of Piqray for the patient.
Comparative Efficacy in Breast Cancer
Both Verzenio and Piqray have shown efficacy in the treatment of breast cancer, but they target different mechanisms within the cancer cells. The choice between these medications is often based on the specific characteristics of the patient's cancer, such as the presence of certain hormone receptors or genetic mutations. The efficacy of these drugs is also dependent on whether they are used in combination with other treatments or as a standalone therapy. Clinical trials and ongoing research continue to define the best use of these medications to optimize outcomes for breast cancer patients.
Conclusion
Verzenio and Piqray represent important advances in the treatment of HR+, HER2- advanced or metastatic breast cancer. Their efficacy has been established through rigorous clinical trials, with Verzenio targeting the CDK4/6 pathway and Piqray targeting the PI3K pathway in patients with specific genetic alterations. As with all cancer treatments, the effectiveness of these drugs can vary from patient to patient, and their use should be individualized based on the tumor's specific characteristics and the patient's overall treatment plan. It is imperative that healthcare providers stay informed about the latest evidence to make the best therapeutic decisions for their patients.
Regulatory Agency Approvals
Verzenio/Verzenios
Piqray
Access Verzenio/Verzenios or Piqray today
If Verzenio/Verzenios or Piqray are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us